Targeted Oncology |
Verstovsek Highlights QoL Benefits With Ruxolitinib in Patients With PV
Targeted Oncology Findings from that trial showed that 60% of patients treated with ruxolitinib achieved hematocrit control without phlebotomy, compared with 20% of patients who received best available therapy. The primary endpoint of the trial looked specifically at ... |
from phlebotomy - Google News http://bit.ly/2Rm8alR
No comments:
Post a Comment